PARIS, France, May 28, 2026
Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration (FDA) granting Priority Review to the company’s New Drug Application (NDA) for venglustat, an investigational oral therapy for Type 3 Gaucher Disease (GD3). The designation brings the treatment one step closer to potentially becoming the first approved therapy in the United States specifically targeting the neurological manifestations of GD3, a rare and progressive lysosomal storage disorder. The FDA has assigned a target action date of November 25, 2026, highlighting the urgent unmet medical need associated with this debilitating condition.
FDA Priority Review Highlights Potential First-in-Class Therapy
Type 3 Gaucher Disease is a rare inherited disorder characterized by the accumulation of harmful glycosphingolipids in multiple organs, including the liver, spleen, bone marrow, lungs, and most critically, the central nervous system (CNS). Unlike other forms of Gaucher disease, GD3 involves progressive neurological symptoms such as impaired coordination, balance difficulties, cognitive decline, and neuroinflammation. Currently, patients have limited treatment options, as available enzyme replacement therapies primarily address systemic manifestations and do not effectively penetrate the brain.
Venglustat is designed to cross the blood-brain barrier, enabling it to target the neurological component of the disease directly. As a novel glucosylceramide synthase inhibitor (GCSi), the therapy works by reducing the production and accumulation of glycosphingolipids that drive disease progression. If approved, venglustat could transform the treatment landscape for patients living with GD3 by addressing both systemic and neurological disease manifestations through a convenient oral treatment approach.
The FDA’s Priority Review designation is reserved for therapies that may offer significant improvements in the treatment, diagnosis, or prevention of serious diseases. The decision underscores the clinical promise of venglustat and reinforces Sanofi’s leadership in the development of therapies for rare genetic and lysosomal storage disorders.
Advertisement
Phase 3 LEAP2MONO Trial Demonstrates Strong Clinical Benefits
The NDA submission is supported by positive results from the Phase 3 LEAP2MONO clinical trial, which evaluated the efficacy and safety of once-daily oral venglustat in both adult and pediatric patients aged 12 years and older with neurological manifestations of GD3. Participants enrolled in the study had previously achieved stabilization of systemic disease symptoms through enzyme replacement therapy.
The trial successfully met both primary endpoints, demonstrating significant improvements in neurological function compared with continued enzyme replacement therapy. The study also met three of four key secondary endpoints, providing further evidence of the therapy’s clinical benefit. Researchers observed meaningful improvements in measures of coordination, cognitive function, and disease-related biomarkers, supporting the drug’s potential to alter disease progression.
Importantly, venglustat was generally well tolerated, with no new safety concerns identified during the study. The most frequently reported adverse events included headache, nausea, diarrhea, and spleen enlargement. The favorable safety profile, combined with strong efficacy findings, provides a compelling foundation for regulatory review and potential approval.
Expanding Sanofi’s Leadership in Rare Disease Innovation
Venglustat has already received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for GD3, reflecting both the severity of the disease and the therapy’s potential clinical impact. In addition to ongoing U.S. review, the treatment is currently undergoing regulatory assessment in the European Union, with additional global submissions planned throughout 2026.
The candidate represents a significant addition to Sanofi’s growing rare disease portfolio, particularly within lysosomal storage disorders, where the company has long maintained a strong presence. By targeting the underlying biological mechanisms driving neurological disease progression, venglustat exemplifies the next generation of precision therapies designed to address previously untreatable aspects of rare genetic disorders.
With Priority Review now underway, the healthcare community will closely watch the upcoming FDA decision. If approved, venglustat could become the first therapy specifically developed to treat the neurological manifestations of Type 3 Gaucher Disease, offering new hope to patients and families affected by one of the most challenging forms of this rare inherited disorder. The milestone further reinforces Sanofi’s commitment to advancing innovative therapies that address critical unmet needs in rare diseases worldwide.
Source: Sanofi press release
